CU24316B1 - Nuevos derivados fosfatos de 1,2,3,4-tetraisoquinolina amida fenilo, métodos de preparación de los mismos y composiciones farmacéuticas que los contienen - Google Patents
Nuevos derivados fosfatos de 1,2,3,4-tetraisoquinolina amida fenilo, métodos de preparación de los mismos y composiciones farmacéuticas que los contienenInfo
- Publication number
- CU24316B1 CU24316B1 CUP2014000095A CU20140095A CU24316B1 CU 24316 B1 CU24316 B1 CU 24316B1 CU P2014000095 A CUP2014000095 A CU P2014000095A CU 20140095 A CU20140095 A CU 20140095A CU 24316 B1 CU24316 B1 CU 24316B1
- Authority
- CU
- Cuba
- Prior art keywords
- formula
- compounds
- preparation
- tetraisoquinolina
- phyphate
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract 2
- 241000670727 Amida Species 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 7
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 abstract 1
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 abstract 1
- 206010041067 Small cell lung cancer Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- 230000006909 anti-apoptosis Effects 0.000 abstract 1
- 150000007942 carboxylates Chemical class 0.000 abstract 1
- 150000001735 carboxylic acids Chemical class 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 abstract 1
- 208000000587 small cell lung carcinoma Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1092—Details
- A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1357259A FR3008979B1 (fr) | 2013-07-23 | 2013-07-23 | Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20140095A7 CU20140095A7 (es) | 2016-02-29 |
| CU24316B1 true CU24316B1 (es) | 2018-02-08 |
Family
ID=50288170
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CUP2014000095A CU24316B1 (es) | 2013-07-23 | 2014-07-23 | Nuevos derivados fosfatos de 1,2,3,4-tetraisoquinolina amida fenilo, métodos de preparación de los mismos y composiciones farmacéuticas que los contienen |
Country Status (48)
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| FR3008976A1 (fr) * | 2013-07-23 | 2015-01-30 | Servier Lab | "nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent" |
| FR3008977A1 (fr) | 2013-07-23 | 2015-01-30 | Servier Lab | Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| UY37316A (es) * | 2016-07-07 | 2018-01-31 | Servier Lab | Dispersión sólida farmacéutica de un inhibidor de bcl-2, composiciones farmacéuticas de ésta, y usos para el tratamiento de cáncer |
| UA125138C2 (uk) * | 2016-07-22 | 2022-01-19 | Ле Лаборатуар Сервьє | Комбінація інгібітора bcl-2 та інгібітора mcl-1, їхнє застосування і фармацевтичні композиції |
| AU2017300738A1 (en) * | 2016-07-22 | 2019-02-07 | Les Laboratoires Servier | Combination of a BCL-2 inhibitor and a MCL-1 inhibitor, uses and pharmaceutical compositions thereof |
| WO2018158225A1 (en) | 2017-02-28 | 2018-09-07 | Les Laboratoires Servier | Combination of a bcl-2 inhibitor and a mdm2 inhibitor, uses and pharmaceutical compositions thereof |
| EA039621B1 (ru) * | 2017-06-09 | 2022-02-17 | Ле Лаборатуар Сервье | Комбинация bcl-2 ингибитора и mcl-1 ингибитора, их применения и фармацевтические композиции |
| AR112440A1 (es) * | 2017-07-06 | 2019-10-30 | Servier Lab | Forma cristalina de un inhibidor de bcl-2, un proceso para su preparación y composiciones farmacéuticas que la contienen |
| FR3072679B1 (fr) * | 2017-10-25 | 2020-10-30 | Servier Lab | Nouveaux derives macrocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| IL276398B2 (en) | 2018-01-31 | 2026-03-01 | Deciphera Pharmaceuticals Llc | Combination therapy for mastocytosis |
| CN118416236A (zh) | 2018-01-31 | 2024-08-02 | 德西费拉制药有限责任公司 | 治疗胃肠道间质瘤的组合疗法 |
| WO2020185812A1 (en) | 2019-03-11 | 2020-09-17 | Teva Pharmaceuticals International Gmbh | Solid state forms of ripretinib |
| TWI878335B (zh) | 2019-08-12 | 2025-04-01 | 美商迪賽孚爾製藥有限公司 | 治療胃腸道基質瘤方法 |
| EP4013412B1 (en) | 2019-08-12 | 2026-01-28 | Deciphera Pharmaceuticals, LLC | Ripretinib for treating gastrointestinal stromal tumors |
| CN110606860B (zh) * | 2019-09-29 | 2021-12-10 | 上海勋和医药科技有限公司 | 一种吡啶磺酰胺磷酸酯类化合物、其制备方法及其用途 |
| MX2022008103A (es) | 2019-12-30 | 2022-09-19 | Deciphera Pharmaceuticals Llc | Formulaciones de inhibidores de la cinasa amorfa y metodos de estas. |
| EP4084779B1 (en) | 2019-12-30 | 2024-10-09 | Deciphera Pharmaceuticals, LLC | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
| JP7773734B2 (ja) * | 2021-03-12 | 2025-11-20 | エイル セラピューティクス，インコーポレイテッド | Ｂｃｌ－２阻害剤としてのテトラヒドロインドリジン－１－カルボキサミドを有する化合物 |
| US20250002491A1 (en) | 2021-10-04 | 2025-01-02 | Forx Therapeutics Ag | N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer |
| US20250387504A1 (en) | 2022-05-20 | 2025-12-25 | Novartis Ag | Antibody-drug conjugates of antineoplastic compounds and methods of use thereof |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
| PY24103486A (es) | 2023-11-22 | 2025-06-06 | Servier Lab | Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos |
| AR134424A1 (es) | 2023-11-22 | 2026-01-14 | Novartis Ag | Conjugados de anticuerpo anti-cd7-fármaco y métodos de uso de los mismos |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1501514B1 (en) * | 2002-05-03 | 2012-12-19 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| US20050124614A1 (en) * | 2002-07-03 | 2005-06-09 | Axys Pharmaceuticals, Inc. | 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis |
| GB0224557D0 (en) * | 2002-10-22 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
| AU2006331765A1 (en) * | 2005-12-22 | 2007-07-05 | Wyeth | Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3(2H)-isoquinolones and use thereof as kinase inhibitor |
| US7902218B2 (en) * | 2006-12-12 | 2011-03-08 | Bristol-Myers Squibb Company | Substituted tetrahydroisoquinolines as β-secretase inhibitors |
| MY162157A (en) * | 2007-04-16 | 2017-05-31 | Abbott Lab | Substituted indole mcl-1 inhibitors |
| MX2009012610A (es) | 2007-05-22 | 2009-12-11 | Astellas Pharma Inc | Compuesto de tetrahidroisoquinolina 1-sustituido. |
| WO2009102468A1 (en) * | 2008-02-13 | 2009-08-20 | Cgi Pharmaceuticals, Inc. | 6-aryl-imidaz0[l, 2-a] pyrazine derivatives, method of making, and method of use thereof |
| WO2010080503A1 (en) * | 2008-12-19 | 2010-07-15 | Genentech, Inc. | Heterocyclic compounds and methods of use |
| TWI520960B (zh) * | 2010-05-26 | 2016-02-11 | 艾伯維有限公司 | 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑 |
| US20120301080A1 (en) | 2011-05-23 | 2012-11-29 | Senko Advanced Components, Inc. | True one piece housing fiber optic adapter |
| BR112014015308A8 (pt) | 2011-12-23 | 2017-06-13 | Novartis Ag | compostos para inibição da interação de bcl2 com contrapartes de ligação |
| EP2794591A1 (en) | 2011-12-23 | 2014-10-29 | Novartis AG | Compounds for inhibiting the interaction of bcl2 with binding partners |
| WO2013096051A1 (en) | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
| EP2794592A1 (en) | 2011-12-23 | 2014-10-29 | Novartis AG | Compounds for inhibiting the interaction of bcl2 with binding partners |
| US9126980B2 (en) | 2011-12-23 | 2015-09-08 | Novartis Ag | Compounds for inhibiting the interaction of BCL2 with binding partners |
| CN103177906A (zh) | 2011-12-26 | 2013-06-26 | 西门子公司 | 用于中压开关设备的断路器 |
| ITPR20110103A1 (it) | 2011-12-27 | 2013-06-28 | G E A F S R L | Metodo e apparato per la sterilizzazione di una soluzione liquida mediante radio frequenza |
| US9114953B2 (en) | 2011-12-29 | 2015-08-25 | Inventio Ag | Emergency operation of elevators based on an indicated emergency condition |
| FR2986002B1 (fr) * | 2012-01-24 | 2014-02-21 | Servier Lab | Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| DE212013000059U1 (de) | 2012-01-24 | 2014-09-11 | Danfoss Power Electronics A/S | Entfeuchter |
-
2013
- 2013-07-23 FR FR1357259A patent/FR3008979B1/fr active Active
-
2014
- 2014-07-08 PH PH12014000194A patent/PH12014000194B1/en unknown
- 2014-07-09 JO JOP/2014/0222A patent/JO3160B1/ar active
- 2014-07-09 AP AP2014007773A patent/AP2014007773A0/xx unknown
- 2014-07-09 SG SG10201403939WA patent/SG10201403939WA/en unknown
- 2014-07-10 MY MYPI2014701887A patent/MY173258A/en unknown
- 2014-07-10 PE PE2014001093A patent/PE20150218A1/es active IP Right Grant
- 2014-07-10 EC ECIEPI20148757A patent/ECSP14008757A/es unknown
- 2014-07-10 IL IL233580A patent/IL233580B/en active IP Right Grant
- 2014-07-11 CR CR20140336A patent/CR20140336A/es unknown
- 2014-07-11 TN TNP2014000301A patent/TN2014000301A1/fr unknown
- 2014-07-11 UY UY35661A patent/UY35661A/es unknown
- 2014-07-11 AU AU2014203808A patent/AU2014203808B2/en active Active
- 2014-07-14 CA CA2856886A patent/CA2856886C/fr active Active
- 2014-07-15 MD MDA20140073A patent/MD4551C1/ro not_active IP Right Cessation
- 2014-07-15 MA MA37213A patent/MA37213B1/fr unknown
- 2014-07-15 DO DO2014000163A patent/DOP2014000163A/es unknown
- 2014-07-15 CL CL2014001865A patent/CL2014001865A1/es unknown
- 2014-07-17 UA UAA201408109A patent/UA119738C2/uk unknown
- 2014-07-17 SV SV2014004771A patent/SV2014004771A/es unknown
- 2014-07-21 GE GEAP201413528A patent/GEP201706704B/en unknown
- 2014-07-22 EP EP14178030.4A patent/EP2829545B1/fr active Active
- 2014-07-22 WO PCT/FR2014/051887 patent/WO2015011399A1/fr not_active Ceased
- 2014-07-22 BR BR102014017997A patent/BR102014017997B1/pt active IP Right Grant
- 2014-07-22 SA SA114350669A patent/SA114350669B1/ar unknown
- 2014-07-22 AR ARP140102712A patent/AR097008A1/es unknown
- 2014-07-22 HU HUE14178030A patent/HUE029616T2/en unknown
- 2014-07-22 SI SI201430059A patent/SI2829545T1/sl unknown
- 2014-07-22 EA EA201400754A patent/EA027444B1/ru unknown
- 2014-07-22 NI NI201400080A patent/NI201400080A/es unknown
- 2014-07-22 ME MEP-2016-208A patent/ME02641B/me unknown
- 2014-07-22 PT PT141780304T patent/PT2829545T/pt unknown
- 2014-07-22 RS RS20160693A patent/RS55098B1/sr unknown
- 2014-07-22 ES ES14178030.4T patent/ES2593417T3/es active Active
- 2014-07-22 JP JP2014148946A patent/JP5894638B2/ja active Active
- 2014-07-22 US US14/337,577 patent/US9115159B2/en active Active
- 2014-07-22 MX MX2014008866A patent/MX351467B/es active IP Right Grant
- 2014-07-22 RU RU2014130129A patent/RU2617682C2/ru active
- 2014-07-22 TW TW103125160A patent/TWI527824B/zh not_active IP Right Cessation
- 2014-07-22 DK DK14178030.4T patent/DK2829545T3/en active
- 2014-07-22 PL PL14178030.4T patent/PL2829545T3/pl unknown
- 2014-07-22 ZA ZA2014/05418A patent/ZA201405418B/en unknown
- 2014-07-23 KR KR1020140093393A patent/KR101713103B1/ko active Active
- 2014-07-23 CN CN201410354089.1A patent/CN104341451B/zh active Active
- 2014-07-23 CU CUP2014000095A patent/CU24316B1/xx unknown
-
2015
- 2015-06-01 HK HK15105213.3A patent/HK1204623A1/xx unknown
- 2015-07-16 US US14/800,871 patent/US9597341B2/en active Active
-
2016
- 2016-07-18 CY CY20161100696T patent/CY1117834T1/el unknown
- 2016-09-20 HR HRP20161202TT patent/HRP20161202T8/hr unknown
- 2016-12-23 KR KR1020160177980A patent/KR20170001694A/ko not_active Withdrawn
-
2017
- 2017-02-06 US US15/425,119 patent/US20170143746A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU24316B1 (es) | Nuevos derivados fosfatos de 1,2,3,4-tetraisoquinolina amida fenilo, métodos de preparación de los mismos y composiciones farmacéuticas que los contienen | |
| CY1121744T1 (el) | Παραγωγα c4-μονομεθυλο-τριτερπενοειδους και μεθοδοι χρησης αυτων | |
| CY1121776T1 (el) | C17-αλκανοδιυλιο και παραγωγα αλκενοδιυλιου του ολεανολικου οξεος και μεθοδοι χρησης αυτων | |
| MX377552B (es) | Proceso para preparar un compuesto antiviral de formula i. | |
| AR097158A1 (es) | Polimorfo de inhibidores de tirosina quinasa de bazo (syk) | |
| EA201592144A1 (ru) | Производное фенола, способ его получения и его применение в медицине | |
| JO3221B1 (ar) | مركبات حمض داي ميثيل - بنزويك مفيدة لعلاج الحالات الالتهابية | |
| EA201291217A1 (ru) | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-2-ТИЕНИЛМЕТИЛБЕНЗОЛА КАК ИНГИБИТОРЫ НЗПГ | |
| AR088551A1 (es) | Conjugados de hidromorfona con acido benzoico, derivados de acido benzoico y acido heteroarilcarboxilico; profarmacos, metodos de preparacion y uso de los mismos | |
| PH12015501752B1 (en) | Substituted bisphenyl butanoic phosphonic acid derivatives as nep inhibitors | |
| PH12015502802A1 (en) | Formulation comprising a hypolipidemic agent | |
| AR105494A1 (es) | Método para preparar derivados de ácido 3-(2-anilino-1-ciclohexil-1h-bencimidazol-5-il)propanoico sustituido | |
| BR112014004523A2 (pt) | composto e composição aromatizante | |
| AR074545A1 (es) | Proceso de preparacion de dihidroetorfina | |
| MX2020004842A (es) | Compuestos heterociclicos antiinfecciosos y sus usos. | |
| WO2020132471A8 (en) | Crystalline and salt forms of an organic compound and pharmaceutical compositions thereof | |
| AR081034A1 (es) | Derivados de n-heteroaril tetrahidro-isoquinolina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades del sistema nervioso central | |
| AR041937A1 (es) | Proceso para la preparacion de derivados de carboestirilo | |
| MX2020009462A (es) | Procesos para la preparación de compuestos de pirimidinilciclopentano. | |
| ES2524086T3 (es) | Nuevo método para la preparación de ezetimiba | |
| EA201591487A1 (ru) | Производные замещенной бисфенилбутановой кислоты в качестве ингибиторов nep с улучшенной in vivo эффективностью | |
| AR082593A1 (es) | Proceso para la preparacion de pirazoles | |
| CY1116477T1 (el) | Μεθοδος εnzυμatiκης συνθεσης toy (7s)-3,4-διμεθοξυδικυκλο[4.2.0] οκτα-1,3,5-τριενo-7-καρβοξυλικου οξεος ή εστερων αυτου και εφαρμογη στην συνθεση της ιβαμπραδινης και των αλατων αυτης | |
| CY1120482T1 (el) | Μεθοδος συνθεσης 3,4-διμεθοξυδικυκλο[4.2.0]οκτα-1,3,5-τριενο-7-καρβονιτριλιου και εφαρμογη στη συνθεση της ιβαμπραδινης και των αλατων προσθηκης αυτης με ενα φαρμακευτικως αποδεκτο οξy | |
| NZ623265A (en) | Stilbenoid compounds as inhibitors for squamous carcinoma and hepatoma and uses thereof |